The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors

被引:2
|
作者
Pavel, Marianne [1 ]
Dromain, Clarisse [2 ]
Ronot, Maxime [3 ]
Schaefer, Niklaus [2 ]
Mandair, Dalvinder [4 ]
Gueguen, Delphine [5 ]
Elvira, David [5 ]
Jegou, Simon [6 ]
Balazard, Felix [6 ]
Dehaene, Olivier [6 ]
Schutte, Kathryn [6 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg, Dept Med 1, Erlangen, Germany
[2] Lausanne Univ Hosp, Lausanne, Switzerland
[3] Beaujon Hosp, Clichy, France
[4] Royal Free Hosp, London, England
[5] Ipsen, Boulogne Billancourt, France
[6] Owkin, Paris, France
关键词
artificial intelligence; deep learning; neuroendocrine tumors; progression-free survival; RECIST; CONSENSUS GUIDELINES; CLINICAL UTILITY; CHROMOGRANIN-A; DIAGNOSIS; METASTASES; MANAGEMENT; RADIOMICS; RECIST;
D O I
10.2217/fon-2022-1136
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary - The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumorsNeuroendocrine tumors (NET) are slow-growing cancers. How well cancers respond to treatment is usually measured using 'Response Evaluation Criteria in Solid Tumors (RECIST)', which is based on measuring the size of tumors. RECIST is not well suited for assessing NETs as these tumors often grow slowly and rarely shrink significantly, so it is difficult to tell whether a treatment has any effect. A better way of measuring how well NETs are responding to treatment is needed, to ensure that patients receive the right treatment as early as possible.The RAISE project aimed to use a type of artificial intelligence (AI) called 'deep learning' to examine images of NETs, taken from patients in a clinical trial of treatment with lanreotide, to help predict how they might respond to treatment. These images were analyzed by the deep learning AI to see if there are any features of tumors, other than shape or size, that may help to predict response to treatment.The project showed that this technology can detect features in images of NETs, other than the shape and size of tumors, that are useful for predicting how well a treatment might work for an individual patient. However, this technology could not improve prediction of how well a treatment would work at an earlier stage compared with other currently used indicators.Overall, further research and work is needed to improve this technology. However, these results show that deep learning may have the potential to improve prediction of treatment response in patients with NETs. Aim: The RAISE project assessed whether deep learning could improve early progression-free survival (PFS) prediction in patients with neuroendocrine tumors. Patients & methods: Deep learning models extracted features from CT scans from patients in CLARINET (NCT00353496) (n = 138/204). A Cox model assessed PFS prediction when combining deep learning with the sum of longest diameter ratio (SLDr) and logarithmically transformed CgA concentration (logCgA), versus SLDr and logCgA alone. Results: Deep learning models extracted features other than lesion shape to predict PFS at week 72. No increase in performance was achieved with deep learning versus SLDr and logCgA models alone. Conclusion: Deep learning models extracted relevant features to predict PFS, but did not improve early prediction based on SLDr and logCgA.
引用
收藏
页码:2185 / 2199
页数:15
相关论文
共 50 条
  • [31] Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors
    Ter-Minassian, Monica
    Zhang, Sui
    Brooks, Nichole V.
    Brais, Lauren K.
    Chan, Jennifer A.
    Christiani, David C.
    Lin, Xihong
    Gabriel, Sylvie
    Dinet, Jerome
    Kulke, Matthew H.
    ONCOLOGIST, 2017, 22 (02) : 165 - 172
  • [32] An autophagy-related four-lncRNA signature helps to predict progression-free survival of neuroblastoma patients
    Wang, Jing
    Meng, Xinyao
    Chen, Ke
    Feng, Jiexiong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib
    Terashima, Takeshi
    Yamashita, Tatsuya
    Takata, Noboru
    Nakagawa, Hidetoshi
    Toyama, Tadashi
    Arai, Kuniaki
    Kitamura, Kazuya
    Yamashita, Taro
    Sakai, Yoshio
    Mizukoshi, Eishiro
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY RESEARCH, 2016, 46 (07) : 650 - 656
  • [34] Multi-parameter MRI radiomic features may contribute to predict progression-free survival in patients with WHO grade II meningiomas
    Zeng, Qiang
    Tian, Zhongyu
    Dong, Fei
    Shi, Feina
    Xu, Penglei
    Zhang, Jianmin
    Ling, Chenhan
    Guo, Zhige
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [35] MRI radiomics predicts progression-free survival in prostate cancer
    Jia, Yushan
    Quan, Shuai
    Ren, Jialiang
    Wu, Hui
    Liu, Aishi
    Gao, Yang
    Hao, Fene
    Yang, Zhenxing
    Zhang, Tong
    Hu, He
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [36] Potential prognostic factors in progression-free survival for patients with cervical cancer
    Hui-Hui Chen
    Wei-Yu Meng
    Run-Ze Li
    Qing-Yi Wang
    Yu-Wei Wang
    Hu-Dan Pan
    Pei-Yu Yan
    Qi-Biao Wu
    Liang Liu
    Xiao-Jun Yao
    Min Kang
    Elaine Lai-Han Leung
    BMC Cancer, 21
  • [37] Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures
    Cui, Yongbin
    Li, Zhengjiang
    Xiang, Mingyue
    Han, Dali
    Yin, Yong
    Ma, Changsheng
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [38] Machine learning models predict overall survival and progression free survival of non-surgical esophageal cancer patients with chemoradiotherapy based on CT image radiomics signatures
    Yongbin Cui
    Zhengjiang Li
    Mingyue Xiang
    Dali Han
    Yong Yin
    Changsheng Ma
    Radiation Oncology, 17
  • [39] Potential prognostic factors in progression-free survival for patients with cervical cancer
    Chen, Hui-Hui
    Meng, Wei-Yu
    Li, Run-Ze
    Wang, Qing-Yi
    Wang, Yu-Wei
    Pan, Hu-Dan
    Yan, Pei-Yu
    Wu, Qi-Biao
    Liu, Liang
    Yao, Xiao-Jun
    Kang, Min
    Leung, Elaine Lai-Han
    BMC CANCER, 2021, 21 (01)
  • [40] A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer
    Tanase, Takanori
    Hamada, Chikuma
    Yoshino, Takayuki
    Ohtsu, Atsushi
    ANTICANCER RESEARCH, 2017, 37 (10) : 5851 - 5855